Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review
- PMID: 24033430
- DOI: 10.1111/his.12219
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review
Abstract
Aims: The recent recognition that ovarian carcinoma is composed of five distinct disease entities has served to increase the value of accurate histotyping. Reliable identification of histotypes is essential for the success of studies testing novel therapies, as well as for biomarker discovery research. The aim of this study was to examine the utility of a nine-marker immunohistochemical (IHC) panel, designated the Calculator for Ovarian Subtype Prediction (COSP), to reliably reproduce the consensus diagnosis of two expert gynaecological pathologists.
Methods and results: A total of 423 cases from the AGO-OVAR11 trial were evaluated using the COSP IHC panel, and compared to original diagnoses from >100 local contributing pathologists and independent expert gynaecopathology review. The overall concordance between COSP and expert review was 89%; in cases where a local pathologist's diagnosis was confirmed by COSP, the expert gynaecopathologist also agreed in 97.5% of cases.
Conclusions: The incorporation of COSP into a high-throughput diagnostic review algorithm will decrease the need for expert review by identifying a small number of difficult cases that truly require expert review. This modification will serve to increase the efficiency of the diagnostic review process, which will probably serve to reduce operational costs and expedite translational studies on ovarian carcinoma.
Keywords: clinical trial; histological subtype; ovarian cancer; pathology review.
© 2013 John Wiley & Sons Ltd.
Similar articles
-
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.Histopathology. 2014 Jun;64(7):1004-13. doi: 10.1111/his.12349. Epub 2014 Mar 7. Histopathology. 2014. PMID: 24329781
-
Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.Br J Cancer. 2017 Jan;116(3):287-292. doi: 10.1038/bjc.2016.416. Epub 2016 Dec 22. Br J Cancer. 2017. PMID: 28006819 Free PMC article.
-
Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.Int J Gynecol Pathol. 2019 Jul;38(4):353-362. doi: 10.1097/PGP.0000000000000530. Int J Gynecol Pathol. 2019. PMID: 29901523 Free PMC article.
-
Ovarian carcinoma pathology and genetics: recent advances.Hum Pathol. 2009 Sep;40(9):1213-23. doi: 10.1016/j.humpath.2009.04.017. Epub 2009 Jun 24. Hum Pathol. 2009. PMID: 19552940 Review.
-
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
Cited by
-
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer.J Cancer Res Clin Oncol. 2021 May;147(5):1421-1430. doi: 10.1007/s00432-021-03558-x. Epub 2021 Mar 3. J Cancer Res Clin Oncol. 2021. PMID: 33660008 Free PMC article.
-
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.Int J Gynecol Pathol. 2016 Sep;35(5):430-41. doi: 10.1097/PGP.0000000000000274. Int J Gynecol Pathol. 2016. PMID: 26974996 Free PMC article.
-
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.Mod Pathol. 2017 Dec;30(12):1748-1759. doi: 10.1038/modpathol.2017.81. Epub 2017 Aug 4. Mod Pathol. 2017. PMID: 28776572
-
Type-specific cell line models for type-specific ovarian cancer research.PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. PLoS One. 2013. PMID: 24023729 Free PMC article.
-
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.Genes Cancer. 2015 Sep;6(9-10):378-398. doi: 10.18632/genesandcancer.76. Genes Cancer. 2015. PMID: 26622941 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical